Evidence map›Paper›PMID 34326167›Full record

ArticleJournal for immunotherapy of cancer2021

WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.

Chunwan Lu, Zhuoqi Liu, John D Klement, Dafeng Yang, Alyssa D Merting, Dakota Poschel, Thomas Albers, Jennifer L Waller, Huidong Shi, Kebin Liu

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. IL1RAJournal of clinical and translational hepatology · 2025
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Chunwan LuSchool of Life Sciences, Tianjin University, Tianjin, China kliu@augusta.edu Chunwanlu@tju.edu.cn.
Zhuoqi LiuDepartment of Biochemistry and Molecular Biology, Nanchang University, Nanchang, China.
John D KlementDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia, USA.
Dafeng YangDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia, USA.
Alyssa D MertingDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia, USA.
Dakota PoschelDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia, USA.
Thomas AlbersGeorgia Cancer Center, Medical College of Georgia, Augusta, Georgia, USA.
Jennifer L WallerDepartment of Population Health Science, Medical College of Georgia, Augusta, Georgia, USA.
Huidong ShiGeorgia Cancer Center, Medical College of Georgia, Augusta, Georgia, USA.
Kebin LiuDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia, USA kliu@augusta.edu Chunwanlu@tju.edu.cn.ORCID 0000-0003-1965-7240
Augusta University · USNanchang University · CNTianjin University · CN

Funding

Role of IRF8 in Tumor Rejection and SuppressionR01CA133085 · NCI · AUGUSTA UNIVERSITY · PI LIU, KEBIN · 2008 to 2019
$2.9M
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCER01CA227433 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2018 to 2022
$2.7M
Function of IRF8 in T cell activation and immune toleranceF30CA236436 · NCI · AUGUSTA UNIVERSITY · PI KLEMENT, JOHN DAVID · 2019 to 2022
$185k
Epigenetic regulation of myeloid regulatory cell accumulation in the tumor microenvironmentF31CA257212 · NCI · AUGUSTA UNIVERSITY · PI MERTING, ALYSSA · 2021 to 2022
$81k
Type I Interferon Regulation of Tumor Cell and Immune Cell Interaction in Human Colon CancerI01CX001364 · VA · CHARLIE NORWOOD VA MEDICAL CENTER · PI KEBIN LIU · 2019 to 2026
–
CSRD VA I01 CX001364NCI NIH HHS F30 CA236436NCI NIH HHS F31 CA257212NCI NIH HHS R01 CA133085NCI NIH HHS R01 CA227433
6 · The paper itself

Abstract

backgroundDespite PD-L1 (Programmed death receptor ligand-1) expression on tumor cells and cytotoxic T lymphocytes tumor infiltration in the tumor microenvironment, human pancreatic cancer stands out as one of the human cancers that does not respond to immune checkpoint inhibitor (ICI) immunotherapy. Epigenome dysregulation has emerged as a major mechanism in T cell exhaustion and non-response to ICI immunotherapy, we, therefore, aimed at testing the hypothesis that an epigenetic mechanism compensates PD-L1 function to render pancreatic cancer non-response to ICI immunotherapy.

methodsTwo orthotopic pancreatic tumor mouse models were used for chromatin immunoprecipitation-Seq and RNA-Seq to identify genome-wide dysregulation of H3K4me3 and gene expression. Human pancreatic tumor and serum were analyzed for osteopontin (OPN) protein level and for correlation with patient prognosis. OPN and PD-L1 cellular location were determined in the tumors using flow cytometry. The function of WDR5-H3K4me3 axis in OPN expression were determined by Western blotting. The function of H3K4me3-OPN axis in pancreatic cancer immune escape and response to ICI immunotherapy was determined in an orthotopic pancreatic tumor mouse model.

resultsMouse pancreatic tumors have a genome-wide increase in H3K4me3 deposition as compared with normal pancreas. OPN and its receptor CD44 were identified being upregulated in pancreatic tumors by their promoter H3K4me3 deposition. OPN protein is increased in both tumor cells and tumor-infiltrating immune cells in human pancreatic carcinoma and is inversely correlated with pancreatic cancer patient survival. OPN is primarily expressed in tumor cells and monocytic myeloid-derived suppressor cells (M-MDSCs), whereas PD-L1 is expressed in tumor cells, M-MDSCs, polymorphonuclear MDSCs and tumor-associated macrophages. WDR5 is essential for H3K4me3-specific histone methyltransferase activity that regulates OPN expression in tumor cells and MDSCs. Inhibition of WDR5 significantly decreased OPN protein level. Inhibition of WDR5 or knocking out of OPN suppressed orthotopic mouse pancreatic tumor growth. Inhibition of WDR5 also significantly increased efficacy of anti-PD-1 immunotherapy in suppression of mouse pancreatic tumor growth in vivo.

conclusionsOPN compensates PD-L1 function to promote pancreatic cancer immune escape. Pharmacological inhibition of the WDR5-H3K4me3 epigenetic axis is effective in suppressing pancreatic tumor immune escape and in improving efficacy of anti-PD-1 immunotherapy in pancreatic cancer.

Indexed as

AnimalsB7-H1 AntigenDisease Models, AnimalEpigenesis, GeneticFemaleHEK293 CellsHistonesHumansImmune Checkpoint InhibitorsIntracellular Signaling Peptides and ProteinsMaleMiceMice, Inbred C57BLOsteopontinPancreatic NeoplasmsTumor EscapeB7-H1 Antigenhistone H3 trimethyl Lys4HistonesImmune Checkpoint InhibitorsIntracellular Signaling Peptides and ProteinsOsteopontinSPP1 protein, humanSpp1 protein, mouseWDR5 protein, humanWdr5 protein, mouseimmune evationimmunotherapymyeloid-derived suppressor cellstumor escape

Identifiers

PMID34326167
PMCPMC8323468
OpenAlexW3184441259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.